Hudson Valley Investment Advisors Inc. ADV Decreases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Hudson Valley Investment Advisors Inc. ADV reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,682 shares of the medical research company’s stock after selling 1,456 shares during the quarter. Thermo Fisher Scientific accounts for 1.4% of Hudson Valley Investment Advisors Inc. ADV’s portfolio, making the stock its 19th largest position. Hudson Valley Investment Advisors Inc. ADV’s holdings in Thermo Fisher Scientific were worth $10,114,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TMO. Savant Capital LLC grew its position in Thermo Fisher Scientific by 0.5% during the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 18 shares in the last quarter. 1776 Wealth LLC grew its position in Thermo Fisher Scientific by 2.4% during the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares in the last quarter. Sugarloaf Wealth Management LLC grew its position in Thermo Fisher Scientific by 6.9% during the fourth quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after purchasing an additional 19 shares in the last quarter. Pacifica Partners Inc. lifted its stake in Thermo Fisher Scientific by 16.5% in the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 20 shares during the last quarter. Finally, Bristlecone Advisors LLC lifted its stake in Thermo Fisher Scientific by 4.1% in the fourth quarter. Bristlecone Advisors LLC now owns 528 shares of the medical research company’s stock valued at $291,000 after acquiring an additional 21 shares during the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $583.09 on Friday. The stock has a 50-day simple moving average of $563.19 and a 200 day simple moving average of $519.43. The stock has a market capitalization of $222.34 billion, a price-to-earnings ratio of 37.74, a P/E/G ratio of 2.45 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.40 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on TMO shares. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 target price for the company. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Raymond James lifted their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $599.00.

Get Our Latest Stock Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.